Skip to main content
SpringerLink
Log in

Measures

  • Chapter
Extravasation of Cytotoxic Agents

  • 93 Accesses

Abstract

Dependent on the extravasated agent, a series of general emergency measures should be considered. Particularly in the case of vesicant substances, these measures are to be completed by substance specific interventions, unfortunately not available for all agents.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Laughlin RA, Landeen JM, Habal MB: The management of inadvertent subcutaneous adriamycin infiltration. Am J Surg 137: 408–412, 1979.

    Article  PubMed  CAS  Google Scholar 

  2. Barlock AL, Howser DM, Hubbard SM: Nursing management of adriamycin extravasation. Am J Nurs 79: 94–96, 1979.

    PubMed  CAS  Google Scholar 

  3. Cox K, Stuart-Harris R, Abdini G, et al: The management of cytotoxicdrug extravasation: guide-lines drawn up by a working party for the Clinical Oncological Society of Australia. Med J Aust 148: 185–189, 1988.

    PubMed  CAS  Google Scholar 

  4. Brown AS, Hoelzer DJ, Piercy SA: Skin necrosis from extravasation of intravenous fluids in children. Plast Reconstr Surg 64: 145–150, 1979.

    Article  PubMed  CAS  Google Scholar 

  5. Heckler FR: Current thoughts on extravasation injuries. Clin Plast Surg 16: 557–563, 1989.

    PubMed  CAS  Google Scholar 

  6. Wang JJ, Cortes E, Sinks LF, et al: Therapeutic effect and toxicity of adriamycin in patients with neoplastic disease. Cancer 28: 837–843, 1971.

    Article  PubMed  CAS  Google Scholar 

  7. Rudolph R, Stein RS, Pattillo RA: Skin ulcers due to adriamycin. Cancer 38: 1087–1094, 1976.

    Article  PubMed  CAS  Google Scholar 

  8. Bowers DG, Lynch JB: Adriamycin extravasation. Plast Reconstr Surg 61: 86–92, 1978.

    Article  PubMed  Google Scholar 

  9. Daniel RK, Williams HB: The free transfer of skin flaps by microvascular anastomoses. An experimental study and a reappraisal. Plast Reconstr Surg 52: 16–31, 1973.

    Article  PubMed  CAS  Google Scholar 

  10. Yosowitz P, Ekland DA, Shaw RC, et al: Peripheral intravenous infiltration necrosis. Ann Surg 182: 553–556, 1975.

    Article  PubMed  CAS  Google Scholar 

  11. Lynch DJ, Key JC, White RR: Management and prevention of infiltration and extravasation injury. Surg Clin North Am 59: 939–949, 1979.

    PubMed  CAS  Google Scholar 

  12. Upton J, Mulliken JB, Murray JE: Major intravenous extravasation injuries. Am J Surg 137: 497–506, 1979.

    Article  PubMed  CAS  Google Scholar 

  13. Sonneveld P, Wassenaar HA, Nooter K: Long persistence of doxorubicin in human skin after extravasation. Cancer Treat Rep 68: 895–896, 1984.

    PubMed  CAS  Google Scholar 

  14. Dorr RT, Dordal MS, Koenig LM, et al: High levels of doxorubicin in the tissues of a patient experiencing extravasation during a 4-day infusion. Cancer 64: 2462–2464, 1989.

    Article  PubMed  CAS  Google Scholar 

  15. Ignoffo RJ, Friedman MA: Therapy of local toxicities caused by extravasation of cancer chemotherapeutic drugs. Cancer Treat Rev 7: 17–27, 1980.

    Article  PubMed  CAS  Google Scholar 

  16. Linder RM, Upton J, Osteen R: Management of extensive doxorubicin hydrochloride extravasation injuries. J Hand Surg 8: 32–38, 1983.

    CAS  Google Scholar 

  17. Montrose PA: Extravasation management. Semin Oncol Nurs 3: 128–132, 1987.

    Article  PubMed  CAS  Google Scholar 

  18. Wetmore N: Extravasation. The dreaded complication. NITA 8: 47–49, 1985.

    PubMed  CAS  Google Scholar 

  19. Köstering H, Nagel GA: Prophylaxe und Therapie von Zytostatika-Hautnekrosen. Onkologie 6: 317–320, 1980.

    Google Scholar 

  20. Faehnrich J: Extravasation. NITA 7: 49–52, 1984.

    CAS  Google Scholar 

  21. Larson DL: Treatment of tissue extravasation by antitumor agents. Cancer 49: 1796–1799, 1982.

    Article  PubMed  CAS  Google Scholar 

  22. Beason R: Antineoplastic vesicant extravasation. J Intraven Nurs 13: 11 1114, 1990.

    Google Scholar 

  23. Cohen SC, DiBella NJ, Michalak JC: Recall injury from adriamycin. Ann Intern Med 83: 232, 1975.

    Article  PubMed  CAS  Google Scholar 

  24. Meehan JL, Sporn JR: Case report of taxol administration via central vein producing a recall reaction at a site of prior taxol extravasation. J Natl Cancer Inst 86: 1250–1251, 1994.

    Article  PubMed  CAS  Google Scholar 

  25. Shapiro J, Richardson GE: Paclitaxel-induced “recall” soft tissue injury occuring at the site of previous extravasation with subsequent intravenous treatment in a different limb. J Clin Oncol 12: 2237–2238, 1994.

    PubMed  CAS  Google Scholar 

  26. Haskell CM, Silverstein MJ, Rangel DM, et al: Multimodality cancer therapy in man — a pilot study of adriamycin by arterial infusion. Cancer 33: 1485–1490, 1974.

    Article  Google Scholar 

  27. Donaldson SS, Glick JM, Wilbur JR: Adriamycin activating a recall phenomenon after radiation therapy. Ann Intern Med 81: 407–408, 1974.

    Article  PubMed  CAS  Google Scholar 

  28. San Angel F: Current controversies in chemotherapy administration. J Intraven Nurs 18: 16–23, 1995.

    Google Scholar 

  29. Mullin S, Beckwith MC, Tyler LS: Prevention and management of antineoplastic extravasation injury. Hosp Pharm 35: 57–76, 2000.

    Google Scholar 

  30. Reilly JJ, Neifeld JP, Rosenberg SA: Clinical course and management of accidental adriamycin extravasation. Cancer 40: 2053–2056, 1977.

    Article  PubMed  CAS  Google Scholar 

  31. MacCara ME: Extravasation: a hazard of intravenous therapy. Drug Intell Clin Pharm 17: 713–717, 1983.

    PubMed  CAS  Google Scholar 

  32. Preuss P, Partoft S: Cytostatic extravasations. Ann Plast Surg 19: 323–327, 1987.

    Article  PubMed  CAS  Google Scholar 

  33. Ayalon A, Anner H, Berlatzky Y, et al: A life-threatening complication of the infusion pump. Lancet 1: 853–854, 1978.

    Article  PubMed  CAS  Google Scholar 

  34. Spiegel RJ: The acute toxicities of chemotherapy. Cancer Treat Rep 8: 197207, 1981.

    Google Scholar 

  35. Hirsh JD, Conlon PF: Implementing guidelines for managing extravasation of antineoplastics. Am J Hosp Pharm 40: 1516–1519, 1983.

    PubMed  CAS  Google Scholar 

  36. David Y, Patish H, Yaffe B, et al: Extravasation injuries. J Orthop Surg Tech 7: 75–86, 1992.

    Google Scholar 

  37. Rozencweig M, Kenis Y, Atassi G, et al: DNA-adriamycin complex: preliminary results in animals and men. Cancer Chemother Rep 6: 131–136, 1975.

    CAS  Google Scholar 

  38. Wilson DW, Grier D, Reimer R, et al: Structure-activity relationship of daunorubicin and its peptide derivatives. J Med Chem 19: 381–384, 1976.

    Article  PubMed  CAS  Google Scholar 

  39. Haskell CM, Canellos GP, Leventhal BG, et al: L-asparaginase: therapeutic and toxic effects in patients with neoplastic disease. N Engl J Med 281: 1028–1034, 1969.

    Article  PubMed  CAS  Google Scholar 

  40. Weiss RB, Bruno S: Hypersensitivity reactions to cancer chemotherapeutic agents. Ann Int Med 94: 66–72, 1981.

    Article  PubMed  CAS  Google Scholar 

  41. Cornwell GG, Pajak TF, McIntyre OR: Hypersensitivity reactions to i.v. melphalan during treatment of multiple myeloma: cancer and leukemia group B experience. Cancer Treat Rep 63: 399–403, 1979.

    PubMed  Google Scholar 

  42. Grem JL, King SA, Costanza ME, et al: Hypersensitivity reactions to trimetrexate. Invest New Drugs 8: 211–214, 1990.

    PubMed  CAS  Google Scholar 

  43. Vogelzang NJ: “Adriamycin flare”: a skin reaction resembling extravasation. Cancer Treat Rep 63: 2067–2069, 1979.

    Google Scholar 

  44. Chait LA, Dinner MI: Ulceration caused by cytotoxic drugs. S Afr Med J 49: 1935–1936, 1975.

    PubMed  CAS  Google Scholar 

  45. Dragon LH, Braine HG: Necrosis of the hand after daunorubicin infusion distal to an arteriovenous fistula. Ann Intern Med 91: 58–59, 1979.

    Article  PubMed  CAS  Google Scholar 

  46. Tully JL, Friedland GH, Baldini LM, et al: Complications of intravenous therapy with steel needles and teflon® catheters. Am J Med 70: 702–706, 1981.

    Article  PubMed  CAS  Google Scholar 

  47. Hankin FM, Louis DS: Extravasation of chemotherapeutic agents. Am Fam Physician 31: 147–150, 1985.

    PubMed  CAS  Google Scholar 

  48. Levey RH, Sallen S, Weinstein H, et al: Surgical techniques for vascular access for chemotherapy in infants and children. J Pediatr Surg 13: 724729, 1978.

    Google Scholar 

  49. Meranze SG, Burke DR, Feurer ID, et al: Spontaneous retraction of indwelling catheters: previously unreported complications. J Parenter Enteral Nutr 12: 310–312, 1988.

    Article  CAS  Google Scholar 

  50. Lokich JJ, Moore C: Drug extravasation in cancer chemotherapy. Ann Int Med 104: 124, 1986.

    PubMed  CAS  Google Scholar 

  51. Dorr RT, Jones SE: Inapparent infiltrations associated with vindesine administration. Med Pediatr Oncol 6: 285–288, 1979.

    Article  PubMed  CAS  Google Scholar 

  52. Hessen JA: Protocol for treatment of vesicant antineoplastic extravasation. Hosp Pharm 24: 705–709, 1989.

    Google Scholar 

  53. Dorr RT: Antidotes to vesicant chemotherapy extravasations. Blood Rev 4: 41–60, 1990.

    Article  PubMed  CAS  Google Scholar 

  54. Harwood KV, Aisner J: Treatment of chemotherapy extravasation: current status. Cancer Treat Rep 68: 939–945, 1984.

    PubMed  CAS  Google Scholar 

  55. Scuderi N, Onesti MG: Antitumor agents: extravasation, management, and surgical treatment. Ann Plast Surg 32: 39–44, 1999.

    Article  Google Scholar 

  56. Krämer I: Zytostatika-Paravasate-Set. Krankenhauspharmazie 13: 154160, 1992.

    Google Scholar 

  57. Bertelli G, Gozza A, Forno GB, et al: Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study. J Clin Oncol 13: 2851–2855, 1995.

    PubMed  CAS  Google Scholar 

  58. Owen 0E, Dellatorre DL, van Scott EJ, et al: Accidental intramuscular injection of mechlorethamine. Cancer 45: 2225–2226, 1980.

    Article  PubMed  CAS  Google Scholar 

  59. Petro JA, Graham WP, Miller SH, et al: Experimental and clinical studies of ulcers induced with adriamycin. Surg Forum 30: 535–537, 1979.

    PubMed  CAS  Google Scholar 

  60. Hajarizadeh H, Lebredo L, Barrie R, et al: Protective effect of doxorubicin in vitamin C or dimethylsulfoxide against skin ulceration in the pig. Ann Surg Oncol 1: 411–414, 1994.

    Article  PubMed  CAS  Google Scholar 

  61. Schwartsmann G, Sander EB, Vinholes J, et al: N-acetylcysteine protects skin lesion induced by local extravasation of doxorubicin in a rat model. Am J Pediatr Hematol Oncol 14: 280–281, 1992.

    Article  PubMed  CAS  Google Scholar 

  62. Nobbs P, Barr RD: Soft-tissue injury caused by antineoplastic drugs is inhibited by topical dimethyl sulphoxide and alpha tocopherol. Br J Cancer 48: 873–876, 1983.

    Article  PubMed  CAS  Google Scholar 

  63. Ludwig CU, Stoll HR, Obrist R, et al: Prevention of cytotoxic drug induced skin ulcers with dimethyl sulfoxide (DMSO) and a-tocopherole. Eur J Cancer Clin Oncol 23: 327–329, 1987.

    Article  PubMed  CAS  Google Scholar 

  64. Averbuch SD, Gaudiano G, Koch TH, et al: Doxorubicin-induced skin necrosis in the swine model: protection with a novel radical dimer. J Clin Oncol 4: 88–94, 1986.

    PubMed  CAS  Google Scholar 

  65. Comas D, Mateu J: Treatment of extravasation of both doxorubicin and vincristine administration in a y-site infusion. Ann Pharmacother 30: 244–246, 1996.

    PubMed  CAS  Google Scholar 

  66. Kolarié K, Zupanc D, Stahl KW, et al: Verhinderung von Extravasatnekrosen als Komplikation nach intravenöser Zytostatikatherapie. Onkologie 11: 238–240, 1988.

    Article  Google Scholar 

  67. Abbes M, Picard JL, Bourgeon Y, et al: A propos de quarante et une complication locales de chimiothérapie. Ann Chir Plast Esthét 31: 149156, 1986.

    Google Scholar 

  68. Tsavaris NB, Karagiaouris P, Tzannou I, et al: Conservative approach to the treatment of chemotherapy-induced extravasation. J Dermatol Surg On-col 16: 519–522, 1990.

    CAS  Google Scholar 

  69. Kraft A, Weinig S, Edinger M, et al: Anthrazyklin-Extravasate. Der Onkologe 6: 674–686, 2000.

    Article  Google Scholar 

  70. Lane P, Vichi P, Bain DL, et al: Temperature dependence studies of adriamycin uptake and cytotoxicity. Cancer Res 47: 4038–4042, 1987.

    PubMed  CAS  Google Scholar 

  71. Dorr RT, Alberts DS, Stone A: Cold protection and heat enhancement of doxorubicin skin toxicity in the mouse. Cancer Treat Rep 69: 431–437, 1985.

    PubMed  CAS  Google Scholar 

  72. Herman TS: Temperature dependence of adriamycin, cis-diamminedichloroplatinum, bleomycin, and 1,3-bis(2-chloroethyl)-1-nitrosourea cytotoxicity in vitro. Cancer Res 43: 517–520, 1983.

    PubMed  CAS  Google Scholar 

  73. Harwood KV, Gonin R: Short term vs. long term local cooling after doxorubicin (DOX) extravasation: an eastern cooperative oncology group (ECOG) study. Proc ASCO 13: 447, 1994.

    Google Scholar 

  74. Harwood KV: Treatment of anthracycline extravasation-recommendations for practice. J Clin Oncol 5: 1705, 1987.

    PubMed  CAS  Google Scholar 

  75. Dorr RT, Alberts DS: Vinca alkaloid skin toxicity: antidote and drug disposition studies in the mouse. J Natl Cancer Inst 74: 113–120, 1985.

    PubMed  CAS  Google Scholar 

  76. Schneider G: Paravasate von Zytostatika. Diagnostik and Therapie. Aina S. Schneider Verlag, 6th edition: 1–17, 1999.

    Google Scholar 

  77. Goodman M, Stewart I, Lydon J, et al: Use caution when managing paclitaxel and taxotere infiltrations. Oncol Nurs Forum 2: 541–542, 1996.

    Google Scholar 

  78. David NA: The pharmacology of dimethylsulfoxide 6544. Ann Rev Pharmacol 12: 353–374, 1972.

    Article  PubMed  CAS  Google Scholar 

  79. Kligman AM: Topical pharmacology and toxicology of dimethyl sulfoxide — part I. JAMA 193: 796–804, 1965.

    Article  PubMed  CAS  Google Scholar 

  80. Görög P, Kovacs IB: Effect of dimethylsulfoxide (DMSO) on various experimental cutaneous reactions. Pharmacology 2: 313–319, 1969.

    Article  PubMed  Google Scholar 

  81. Desai MH, Teres D: Prevention of doxorubicin-induced skin ulcers in the rat and pig with dimethyl sulfoxide (DMSO). Cancer Treat Rep 66: 1371 1374, 1982.

    Google Scholar 

  82. Massart C, Le Tellier C, Gibassier J, et al: Modulation by dimethyl sulphoxide of the toxicity induced by cis-diamminedichloroplatinum in cultured thyrocytes. Toxicol in vitro 7: 87–94, 1993.

    Article  PubMed  CAS  Google Scholar 

  83. Jones MM, Basinger MA, Field L, et al: Coadministration of dimethyl sulfoxide reduces cisplatin nephrotoxicity. Anticancer Res 11: 1939–1942, 1991.

    PubMed  CAS  Google Scholar 

  84. Olver IN, Aisner J, Hament A, et al: A prospective study of topical dimethyl sulfoxide for treating anthracycline extravasation. J Clin Oncol 6: 1732 1735, 1988.

    Google Scholar 

  85. Bertelli G, Dini D, Forno GB, et al: Hyaluronidase as an antidote to extravasation of vinca alkaloids: clinical results. J Cancer Res Clin Oncol 120: 505–506, 1994.

    Article  PubMed  CAS  Google Scholar 

  86. Cohen MH: Amelioration of adriamycin skin necrosis: an experimental study. Cancer Treat Rep 63: 1003–1004, 1979.

    PubMed  CAS  Google Scholar 

  87. Laurie SW, Wilson KL, Kernahan DA, et al: Intravenous extravasation injuries: the effectiveness of hyaluronidase in their treatment. Ann Plast Surg 13: 191–194, 1984.

    Article  PubMed  CAS  Google Scholar 

  88. Disa JJ, Chang RR, Mucci SJ, et al: Prevention of adriamycin-induced full-thickness skin loss using hyaluronidase infiltration. Plast Reconstr Surg 101: 370–374, 1998.

    Article  PubMed  CAS  Google Scholar 

  89. Stanley A: Managing complications of chemotherapy. In: Allwood M, Stanley A, Wright P (eds) The Cytotoxics Handbook. Radcliffe Medical Press, 3rd edition: 105–124, 1997.

    Google Scholar 

  90. Schwartzman J, Henderson AT, King WE: Hyaluronidase in fluid administration. J Pediatr 33: 267–273, 1948.

    Article  PubMed  CAS  Google Scholar 

  91. Bartkowski-Dodds L, Daniels JR: Use of sodium bicarbonate as a means of ameliorating doxorubicin-induced dermal necrosis in rats. Cancer Che-mother Pharmacol 4: 179–181, 1980.

    CAS  Google Scholar 

  92. Barr RD, Sertic J: Soft-tissue necrosis induced by extravasated cancer chemotherapeutic agents: a study of active intervention. Br J Cancer 44: 267–269, 1981.

    Article  PubMed  CAS  Google Scholar 

  93. Laskar PA, Ayres JW: Degradation of carmustine in aqueous media. J Pharm Sci 66: 1073–1076, 1977.

    Article  PubMed  CAS  Google Scholar 

  94. Colvin M, Hartner J, Summerfield M: Stability of carmustine in the presence of sodium bicarbonate. Am J Hosp Pharm 37: 677–678, 1980.

    PubMed  CAS  Google Scholar 

  95. Schneider SM, Distelhorst CW: Chemotherapy-induced emergencies. Semin Oncol 16: 572–578, 1989.

    PubMed  CAS  Google Scholar 

  96. Jackson IT, Robinson DW: Severe tissue damage following accidental subcutaneous infusion of bicarbonate solution. Scot Med J 21: 200–201, 1976.

    PubMed  CAS  Google Scholar 

  97. Gaze NR: Tissue necrosis caused by commonly used intravenous infusions. Lancet 2: 417–419, 1978.

    Article  PubMed  CAS  Google Scholar 

  98. Kappel B, Hindenburg AA, Taub RN: Treatment of anthracycline extravasation — a warning against the use of sodium bicarbonate. J Clin Oncol 5: 825–826, 1987.

    PubMed  CAS  Google Scholar 

  99. Groos E, Walker L, Masters JR: Intravesical chemotherapy: studies on the relationship between pH and cytotoxicity. Cancer 58: 1199–1203, 1986.

    Article  PubMed  CAS  Google Scholar 

  100. Tsavaris NB, Komitsopoulou P, Karagiaouris P, et al: Prevention of tissue necrosis due to accidental extravasation of cytostatic drugs by a conservative approach. Cancer Chemother Pharmacol 30: 330–333, 1992.

    Article  PubMed  CAS  Google Scholar 

  101. Howell SB, Taetle R: Effect of sodium thiosulfate on cis-dichloroammineplatinum (II) toxicity and antitumor activity in L1210 leukemia. Cancer Treat Rep 64: 611–616, 1980.

    PubMed  CAS  Google Scholar 

  102. Buchanan GR, Buchsbaum HJ, O’Banion K, et al: Extravasation of dactinomycin, vincristine, and cisplatin: studies in an animal model. Med Pediatr Oncol 13: 375–380, 1985.

    Article  PubMed  CAS  Google Scholar 

  103. Dorr RT, Soble M, Alberts DS: Efficacy of sodium thiosulfate as a local antidote to mechlorethamine skin toxicity in the mouse. Cancer Chemother Pharmacol 22: 299–302, 1988.

    Article  PubMed  CAS  Google Scholar 

  104. Baskin SI, Horowitz AM, Nealley EW: The antidotal action of sodium nitrite and sodium thiosulfate against cyanide poisoning. J Clin Pharmacol 32: 368–375, 1992.

    Article  PubMed  CAS  Google Scholar 

  105. Dorr RT, Alberts DS, Chen HS: The limited role of corticosteroids in ameliorating experimental doxorubicin skin toxicity in the mouse. Cancer Chemother Pharmacol 5: 17–20, 1980.

    Article  PubMed  CAS  Google Scholar 

  106. Coleman JJ, Walker AP, Didolkar MS: Treatment of adriamycin-induced skin ulcers: a prospective controlled study. J Surg Oncol 22: 129–135, 1983.

    Article  PubMed  CAS  Google Scholar 

  107. Rudolph R: Ulcers of the hand and wrist caused by doxorubicin hydrochloride. Orthop Rev 7: 93–95, 1978.

    Google Scholar 

  108. Luedke DW, Kennedy PS, Rietschel RL: Histopathogenesis of skin and subcutaneous injury induced by adriamycin. Plast Reconstr Surg 63: 463465, 1979.

    Google Scholar 

  109. Rudolph R, Larson DL: Etiology and treatment of chemotherapeutic agent extravasation injuries: a review. J Clin Oncol 5: 1116–1126, 1987.

    PubMed  CAS  Google Scholar 

  110. Larson DL: What is the appropriate management of tissue extravasation by antitumor agents? Plast Reconstr Surg 75: 397–402, 1985.

    Article  PubMed  CAS  Google Scholar 

  111. Pitkänen J, Asko-Seljavaara S, Gröhn P, et al: Adriamycin extravasation: surgical treatment and possible prevention of skin and soft-tissue injuries. J Surg Oncol 23: 259–262, 1983.

    Article  PubMed  Google Scholar 

  112. Shenaq SM, Abbase EH, Friedman JD: Soft-tissue reconstruction following extravasation of chemotherapeutic agents. Surg Oncol Clin N Am 5: 825–845, 1996.

    PubMed  CAS  Google Scholar 

  113. Seyfer AE, Solimando DA: Toxic lesions of the hand associated with chemotherapy. J Hand Surg 8: 39–42, 1983.

    CAS  Google Scholar 

  114. Devereux DF, Thibault LE, Boretos J, et al: Th`e quantitative and qualitative impairment of wound healing by adriamycin. Cancer 43: 932–938, 1979.

    Article  PubMed  CAS  Google Scholar 

  115. Devereux DF, Kent H, Brennan MF: Time dependent effects of adriamycin and x-ray therapy on wound healing in the rat. Cancer 45: 2805–2810, 1980.

    Article  PubMed  CAS  Google Scholar 

  116. Devereux DF, Triche TJ, Webber BL, et al: A study of adriamycin-reduced wound breaking strength in rats. Cancer 45: 2811–2815, 1980.

    Article  PubMed  CAS  Google Scholar 

  117. Cohen FJ, Manganaro J, Bezozo RC: Identification of involved tissue during surgical treatment of doxorubicin-induced extravasation necrosis. J Hand Surg 8: 43–45, 1983.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria

    Ines Mader MD

  2. SMZ Floridsdorf, Krankenhaus und Geriatriezentrum, Vienna, Austria

    Patrizia E. Fürst-Weger Mag. pharm

  3. Clinical Division of Oncology, Department of Medicine I, University Hospital, Vienna, Austria

    Robert M. Mader DSc

  4. Anstaltsapotheke, Landeskrankenhaus — Universitätskliniken Innsbruck, Austria

    Elisabeth I. Semenitz MD, Mag. pharm

  5. Kaiser-Franz-Josef Hospital, Vienna, Austria

    Robert Terkola PharmD (Head of Pharmacy)

  6. Apotheke LKH-Univ.-Klinikum Graz, Austria

    Sabine M. Wassertheurer Mag. pharm.

Authors
  1. Ines Mader MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Patrizia E. Fürst-Weger Mag. pharm
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robert M. Mader DSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Elisabeth I. Semenitz MD, Mag. pharm
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Robert Terkola PharmD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sabine M. Wassertheurer Mag. pharm.
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer-Verlag Wien

About this chapter

Cite this chapter

Mader, I., Fürst-Weger, P.E., Mader, R.M., Semenitz, E.I., Terkola, R., Wassertheurer, S.M. (2003). Measures. In: Extravasation of Cytotoxic Agents. Springer, Vienna. https://doi.org/10.1007/978-3-7091-3710-9_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-3710-9_5

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-7091-3712-3

  • Online ISBN: 978-3-7091-3710-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation